Form 4: Amgen CEO Robert Bradway Executes Stock Disposition
Statement of Changes in Beneficial Ownership
Amgen Chairman and CEO Robert A. Bradway reported the disposition of 5,057 shares of common stock to cover tax obligations related to equity vesting.
Summary
- Robert A. Bradway, Chairman, CEO and President of Amgen Inc., disposed of a total of 5,057 shares of common stock on May 2, 2026.
- The shares were disposed of at a price of $329.82 per share.
- The transaction was executed via code 'F', indicating the payment of tax liability by delivering or withholding securities incident to the vesting of a security.
- Following these transactions, the reporting person maintains direct beneficial ownership of 496,805 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the transaction is purely administrative and related to tax obligations rather than a change in investment conviction.
Positives
- The transaction is a routine administrative action related to tax withholding upon the vesting of equity awards, rather than a discretionary open-market sale.
Negatives
- Reduction in the direct shareholding of the company's CEO.
Risks
- None identified; this is a standard regulatory disclosure for executive compensation tax compliance.
Future Outlook
No forward-looking guidance or strategic outlook provided in this regulatory filing.
Industry Context
StockSavvy.ai notes that Form 4 filings regarding tax withholding are standard industry practice for executives at large-cap biopharmaceutical companies and do not typically signal a change in management sentiment regarding company performance.
Comparison to Industry Standards
- The transaction aligns with standard executive compensation practices observed at major pharmaceutical firms like Pfizer, Merck, and AbbVie, where equity vesting triggers mandatory tax withholding via share disposition.
Stakeholder Impact
- Minimal impact on shareholders as the transaction is a non-discretionary tax compliance event.
Key Dates
| Date | Description |
|---|---|
| 05/02/2026 | Date of the reported stock disposition transactions. |
| 05/05/2026 | Date of the filing signature. |
Keywords
Amgen, AMGN, Insider Trading, Form 4, Executive Compensation, Robert Bradway
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.